Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, will announce its full year results for the year ended 30 June 2025 on Tuesday, 14 October 2025 and hold the following analyst briefing and investor presentation.

Analyst briefing

An online briefing for analysts will be hosted by Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer, at 9.30 am on Tuesday, 14 October 2025, to review the full year results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at [email protected].

Share on:

You might also enjoy reading Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Written by: Amilia Stone

Latest Company News

Aptamer and Metir advance real-time water pathogen detection programme

February 17, 2026

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

February 11, 2026

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

Aptamer Group secures £270k in new orders and first cash licensing receipts

January 29, 2026

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence.

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

January 7, 2026

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements.

Aptamer Group signs first licensing deal with Twist Bioscience

December 16, 2025

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

Aptamer Group AGM statement highlights contract wins and growing order book

November 27, 2025

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.